Cargando…
Incidence and characteristics of invasive fungal diseases in allogeneic hematopoietic stem cell transplant recipients: a retrospective cohort study
BACKGROUND: Allogeneic hematopoietic stem cell transplant (HSCT) recipients experience an increased risk for invasive fungal diseases (IFDs). METHODS: This retrospective cohort study at the Medical University of Vienna aspired to assess the incidence, characteristics and the outcome of IFDs as well...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4696168/ https://www.ncbi.nlm.nih.gov/pubmed/26715563 http://dx.doi.org/10.1186/s12879-015-1329-6 |
_version_ | 1782407741413785600 |
---|---|
author | Harrison, Nicole Mitterbauer, Margit Tobudic, Selma Kalhs, Peter Rabitsch, Werner Greinix, Hildegard Burgmann, Heinz Willinger, Birgit Presterl, Elisabeth Forstner, Christina |
author_facet | Harrison, Nicole Mitterbauer, Margit Tobudic, Selma Kalhs, Peter Rabitsch, Werner Greinix, Hildegard Burgmann, Heinz Willinger, Birgit Presterl, Elisabeth Forstner, Christina |
author_sort | Harrison, Nicole |
collection | PubMed |
description | BACKGROUND: Allogeneic hematopoietic stem cell transplant (HSCT) recipients experience an increased risk for invasive fungal diseases (IFDs). METHODS: This retrospective cohort study at the Medical University of Vienna aspired to assess the incidence, characteristics and the outcome of IFDs as well as the associated risk factors in a setting where only 43 % of patients were given systemic antifungal prophylaxis during aplasia. IFDs were classified as probable or proven according to the EORTC/MSG consensus group. All adult patients (n = 242) receiving an allogeneic HSCT at the University Hospital of Vienna from January 2009 to December 2013 were enrolled. RESULTS: The primary outcome of this study was the one-year incidence for IFDs after HSCT, which was 10.3 % (25/242). Overall 28 patients experienced an IFD – 20 probable and 8 proven – with invasive aspergillosis being the predominant IFD (n = 18), followed by invasive candidiasis (n = 7) and pneumocystis pneumonia (n = 3). Patients with an IFD were more likely to be admitted to an intensive care unit (64 % versus 12 %, p < 0.0001) and had a significantly higher mortality in the first year after HSCT (48 % versus 25 %, p = 0.02). Multivariate regression analysis revealed that intensified immunosuppressive therapy (high-dose cortisone and basiliximab or etanercept) because of severe graft-versus-host disease (adjusted odds ratio (AOR) 3.6, p = 0.01) and transplant-associated microangiopathy (AOR 3.7, p = 0.04) were associated with an increased risk for IFD, while antifungal prophylaxis given during aplasia and post-engraftment was associated with a decreased risk (AOR 0.3, p = 0.02). CONCLUSIONS: We documented a one-year incidence for IFDs of 10.3 % and no selection of rare pathogens at a centre with moderate use of antifungal prophylaxis. Intensified immunosuppressive therapy and transplant-associated microangiopathy were significant risk factors for IFDs. |
format | Online Article Text |
id | pubmed-4696168 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-46961682015-12-31 Incidence and characteristics of invasive fungal diseases in allogeneic hematopoietic stem cell transplant recipients: a retrospective cohort study Harrison, Nicole Mitterbauer, Margit Tobudic, Selma Kalhs, Peter Rabitsch, Werner Greinix, Hildegard Burgmann, Heinz Willinger, Birgit Presterl, Elisabeth Forstner, Christina BMC Infect Dis Research Article BACKGROUND: Allogeneic hematopoietic stem cell transplant (HSCT) recipients experience an increased risk for invasive fungal diseases (IFDs). METHODS: This retrospective cohort study at the Medical University of Vienna aspired to assess the incidence, characteristics and the outcome of IFDs as well as the associated risk factors in a setting where only 43 % of patients were given systemic antifungal prophylaxis during aplasia. IFDs were classified as probable or proven according to the EORTC/MSG consensus group. All adult patients (n = 242) receiving an allogeneic HSCT at the University Hospital of Vienna from January 2009 to December 2013 were enrolled. RESULTS: The primary outcome of this study was the one-year incidence for IFDs after HSCT, which was 10.3 % (25/242). Overall 28 patients experienced an IFD – 20 probable and 8 proven – with invasive aspergillosis being the predominant IFD (n = 18), followed by invasive candidiasis (n = 7) and pneumocystis pneumonia (n = 3). Patients with an IFD were more likely to be admitted to an intensive care unit (64 % versus 12 %, p < 0.0001) and had a significantly higher mortality in the first year after HSCT (48 % versus 25 %, p = 0.02). Multivariate regression analysis revealed that intensified immunosuppressive therapy (high-dose cortisone and basiliximab or etanercept) because of severe graft-versus-host disease (adjusted odds ratio (AOR) 3.6, p = 0.01) and transplant-associated microangiopathy (AOR 3.7, p = 0.04) were associated with an increased risk for IFD, while antifungal prophylaxis given during aplasia and post-engraftment was associated with a decreased risk (AOR 0.3, p = 0.02). CONCLUSIONS: We documented a one-year incidence for IFDs of 10.3 % and no selection of rare pathogens at a centre with moderate use of antifungal prophylaxis. Intensified immunosuppressive therapy and transplant-associated microangiopathy were significant risk factors for IFDs. BioMed Central 2015-12-29 /pmc/articles/PMC4696168/ /pubmed/26715563 http://dx.doi.org/10.1186/s12879-015-1329-6 Text en © Harrison et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Harrison, Nicole Mitterbauer, Margit Tobudic, Selma Kalhs, Peter Rabitsch, Werner Greinix, Hildegard Burgmann, Heinz Willinger, Birgit Presterl, Elisabeth Forstner, Christina Incidence and characteristics of invasive fungal diseases in allogeneic hematopoietic stem cell transplant recipients: a retrospective cohort study |
title | Incidence and characteristics of invasive fungal diseases in allogeneic hematopoietic stem cell transplant recipients: a retrospective cohort study |
title_full | Incidence and characteristics of invasive fungal diseases in allogeneic hematopoietic stem cell transplant recipients: a retrospective cohort study |
title_fullStr | Incidence and characteristics of invasive fungal diseases in allogeneic hematopoietic stem cell transplant recipients: a retrospective cohort study |
title_full_unstemmed | Incidence and characteristics of invasive fungal diseases in allogeneic hematopoietic stem cell transplant recipients: a retrospective cohort study |
title_short | Incidence and characteristics of invasive fungal diseases in allogeneic hematopoietic stem cell transplant recipients: a retrospective cohort study |
title_sort | incidence and characteristics of invasive fungal diseases in allogeneic hematopoietic stem cell transplant recipients: a retrospective cohort study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4696168/ https://www.ncbi.nlm.nih.gov/pubmed/26715563 http://dx.doi.org/10.1186/s12879-015-1329-6 |
work_keys_str_mv | AT harrisonnicole incidenceandcharacteristicsofinvasivefungaldiseasesinallogeneichematopoieticstemcelltransplantrecipientsaretrospectivecohortstudy AT mitterbauermargit incidenceandcharacteristicsofinvasivefungaldiseasesinallogeneichematopoieticstemcelltransplantrecipientsaretrospectivecohortstudy AT tobudicselma incidenceandcharacteristicsofinvasivefungaldiseasesinallogeneichematopoieticstemcelltransplantrecipientsaretrospectivecohortstudy AT kalhspeter incidenceandcharacteristicsofinvasivefungaldiseasesinallogeneichematopoieticstemcelltransplantrecipientsaretrospectivecohortstudy AT rabitschwerner incidenceandcharacteristicsofinvasivefungaldiseasesinallogeneichematopoieticstemcelltransplantrecipientsaretrospectivecohortstudy AT greinixhildegard incidenceandcharacteristicsofinvasivefungaldiseasesinallogeneichematopoieticstemcelltransplantrecipientsaretrospectivecohortstudy AT burgmannheinz incidenceandcharacteristicsofinvasivefungaldiseasesinallogeneichematopoieticstemcelltransplantrecipientsaretrospectivecohortstudy AT willingerbirgit incidenceandcharacteristicsofinvasivefungaldiseasesinallogeneichematopoieticstemcelltransplantrecipientsaretrospectivecohortstudy AT presterlelisabeth incidenceandcharacteristicsofinvasivefungaldiseasesinallogeneichematopoieticstemcelltransplantrecipientsaretrospectivecohortstudy AT forstnerchristina incidenceandcharacteristicsofinvasivefungaldiseasesinallogeneichematopoieticstemcelltransplantrecipientsaretrospectivecohortstudy |